Tue, 26 Aug 2008 10:08:38 -0400 PeerView Press http://www.peerviewpress.com Podcast Maker v1.3 - http://www.lemonzdream.com/podcastmaker PeerView Press is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView Press is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes. Thought leader perspectives on current clinical advances in medicine PeerView Press is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView Press is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes. 2007 PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018 webmaster@peerviewpress.com http://podcast.peerviewpress.com/oncology/oncologyalbumart_144.jpg http://www.peerviewpress.com 144 144 Science & Medicine CME, Medical Education, continuing medical education, CME credits, PeerView Press, inSession, inReview, CE, Oncology no PeerView Press In this activity, an expert provides a clinical update on the latest data on molecularly targeted therapies in advanced lung cancer. New strategies with currently approved targeted agents are assessed, and the ongoing exploration of investigational therapies is underscored. Please be sure to view the accompanying (PDF) file or full CME/CE information. In this activity, an expert provides a clinical update on the latest data on molecularly targeted therapies in advanced lung cancer. New strategies with currently approved targeted agents are assessed, and the ongoing exploration of investigational therapies is underscored. http://podcast.peerviewpress.com/oncology/PA04787FCn189.mp3 http://podcast.peerviewpress.com/oncology/PA04787FC_n189.mp3 Tue, 19 Aug 2008 14:34:08 -0400 Science no 00:23:39 ASCO, NSCLC, lung cancer, EGFR, erlotinib, bevacizumab, cetuximab, gefitinib, adenocarcinoma, squamous PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA04787FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA04787FCCMEinfo.pdf Tue, 19 Aug 2008 14:34:08 -0400 Science no 00:00:00 ASCO, NSCLC, lung cancer, EGFR, erlotinib, bevacizumab, cetuximab, gefitinib, adenocarcinoma, squamous PeerView Press In this CME activity, experts discuss currently available and emerging immunotherapies for melanoma, with a focus on adjuvant interferon therapy, vaccine strategies, and CTLA-4 antagonists. Recent clinical trial results are reviewed, and the role, benefits, and limitations of the various immunotherapeutic approaches are debated. Please be sure to view the accompanying (PDF) file or full CME/CE information. In this CME activity, experts discuss currently available and emerging immunotherapies for melanoma, with a focus on adjuvant interferon therapy, vaccine strategies, and CTLA-4 antagonists. Recent clinical trial results are reviewed, and the role, benefits, and limitations of the various immunotherapeutic approaches are debated. http://podcast.peerviewpress.com/oncology/PA04363FCe012.mp3 http://podcast.peerviewpress.com/oncology/PA04363FCe012.mp3 Fri, 08 Aug 2008 11:13:10 -0400 Science no 00:40:50 CTLA-4 antagonists, melanoma, autoimmunity, interferon alpha, immunotherapy, CD40, T cell PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA04363FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA04363FCCMEinfo.pdf Fri, 08 Aug 2008 11:13:05 -0400 Science no 00:00:00 CTLA-4 antagonists, melanoma, autoimmunity, interferon alpha, immunotherapy, CD40, T cell PeerView Press In this CME activity, experts provide an update on novel immunotherapies under evaluation in melanoma, with a focus on anti–CTLA-4 antibodies. The benefits and limitations of currently available standard therapies are described, as well as the need for novel therapies. Efficacy and safety of the CTLA-4 antagonists are discussed, and whether or not the conventional clinical trial endpoints are appropriate for evaluating benefit from such therapies is debated. Additionally, the toxicity profile of the CTLA-4 antagonists and management of the key adverse effects associated with these agents are reviewed. Please be sure to view the accompanying (PDF) file or full CME/CE information. In this CME activity, experts provide an update on novel immunotherapies under evaluation in melanoma, with a focus on anti–CTLA-4 antibodies. The benefits and limitations of currently available standard therapies are described, as well as the need for novel therapies. Efficacy and safety of the CTLA-4 antagonists are discussed, and whether or not the conventional clinical trial endpoints are appropriate for evaluating benefit from such therapies is debated. Additionally, the toxicity profile of the CTLA-4 antagonists and management of the key adverse effects associated with these agents are reviewed. http://podcast.peerviewpress.com/oncology/PA04362FC018.mp3 http://podcast.peerviewpress.com/oncology/PA04362FC018.mp3 Wed, 30 Jul 2008 14:36:41 -0400 Science, Medicine no 00:38:25 CTLA-4 antagonists, temozolomide, dacarbazine, Darthmouth regimen, melanoma PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA04362FC018.pdf http://podcast.peerviewpress.com/oncology/PA04362FC018CMECEinfo.pdf Wed, 30 Jul 2008 14:35:41 -0400 Science, Medicine no 00:00:00 CTLA-4 antagonists, temozolomide, dacarbazine, Darthmouth regimen, melanoma PeerView Press In this educational program, an expert describes the unique safety profile of the antiangiogenic agents in lung cancer, and discusses how to manage some of the key toxicities. Please be sure to view the accompanying (PDF) file or full CME/CE information. In this educational program, an expert describes the unique safety profile of the antiangiogenic agents in lung cancer, and discusses how to manage some of the key toxicities. http://podcast.peerviewpress.com/oncology/PA04435FCn180.mp3 http://podcast.peerviewpress.com/oncology/PA04435FCn180.mp3 Thu, 12 Jun 2008 10:20:06 -0400 Science no 00:21:39 antiangiogenesis, NSCLC, cytotoxics, bevacizumab, febrile neutropenia, sunitinib, sorafenib, vandetanib, toxicities PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA04435FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA04435FCCMEinfo.pdf Thu, 12 Jun 2008 10:20:03 -0400 Science no 00:00:00 antiangiogenesis, NSCLC, cytotoxics, bevacizumab, febrile neutropenia, sunitinib, sorafenib, vandetanib, toxicities PeerView Press In this CME activity, experts discuss the latest perspectives on the treatment of ovarian cancer. Benefits and limitations of current therapies for recurrent ovarian cancer are evaluated, and clinical issues related to management of this disease are debated. Additionally, the emerging role of novel targeted and cytotoxic therapies is reviewed. Please be sure to view the accompanying (PDF) file or full CME/CE information. In this CME activity, experts discuss the latest perspectives on the treatment of ovarian cancer. Benefits and limitations of current therapies for recurrent ovarian cancer are evaluated, and clinical issues related to management of this disease are debated. Additionally, the emerging role of novel targeted and cytotoxic therapies is reviewed. http://podcast.peerviewpress.com/oncology/PA04241FCe017.mp3 http://podcast.peerviewpress.com/oncology/PA04241FCe017.mp3 Fri, 06 Jun 2008 10:38:39 -0400 Science no 00:25:52 CA-125, liposomal doxorubicin, topotecan, capecitabine, ovarian cancer, gemcitabine, bevacizumab, EGFR PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA04241FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA04241FCCMEinfo.pdf Fri, 06 Jun 2008 10:38:37 -0400 Science no 00:00:00 CA-125, liposomal doxorubicin, topotecan, capecitabine, ovarian cancer, gemcitabine, bevacizumab, EGFR PeerView Press In this activity, an expert in breast cancer highlights latest clinical trial data, focusing on the role of more established as well as novel biologic therapies in early stage and advanced breast cancer in the context of a move towards more individualized therapy. Please be sure to view the accompanying (PDF) file or full CME/CE information. In this activity, an expert in breast cancer highlights latest clinical trial data, focusing on the role of more established as well as novel biologic therapies in early stage and advanced breast cancer in the context of a move towards more individualized therapy. http://podcast.peerviewpress.com/oncology/PA04346FCn181.mp3 http://podcast.peerviewpress.com/oncology/PA04346FCn181.mp3 Tue, 27 May 2008 16:56:42 -0400 Science no 00:33:34 antiangiogenic, HER2, bevacizumab, VEGF, SABCS, metastatic breast cancer, trastuzumab PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA04346FCCME.pdf http://podcast.peerviewpress.com/oncology/PA04346FCCMEinfo.pdf Tue, 27 May 2008 16:56:38 -0400 Science no 00:00:00 antiangiogenic, HER2, bevacizumab, VEGF, SABCS, metastatic breast cancer, trastuzumab PeerView Press In this CME activity, experts provide an update on the antineoplastic resistance mechanisms in breast cancer and possible strategies for combating resistance. Through an interactive discussion, resistance mechanisms that have potential clinical relevance are summarized, and treatment options for overcoming or circumventing resistance, including the role of epothilones, are reviewed. In addition, clinical data and practical considerations for use of epothilones in metastatic breast cancer are discussed. Please be sure to view the accompanying (PDF) file or full CME/CE information. In this CME activity, experts provide an update on the antineoplastic resistance mechanisms in breast cancer and possible strategies for combating resistance. Through an interactive discussion, resistance mechanisms that have potential clinical relevance are summarized, and treatment options for overcoming or circumventing resistance, including the role of epothilones, are reviewed. In addition, clinical data and practical considerations for use of epothilones in metastatic breast cancer are discussed. http://podcast.peerviewpress.com/oncology/PA04156FCe010.mp3 http://podcast.peerviewpress.com/oncology/PA04156FCe010.mp3 Wed, 23 Apr 2008 13:58:12 -0400 Science no 00:27:43 MBC, epothilones, ixabepilone, chemotherapy, P-glycoprotein, monoclonal antibodies, paclitaxel, sagopilone PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA04156FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA04156FCCMEinfo.pdf Wed, 23 Apr 2008 13:58:12 -0400 Science no 00:00:00 MBC, epothilones, ixabepilone, chemotherapy, P-glycoprotein, monoclonal antibodies, paclitaxel, sagopilone PeerView Press In this CME/CE activity, experts in oncology highlight latest evidence in advanced/metastatic colorectal cancer (CRC). Latest efficacy and safety data on targeted therapies are reviewed, strategies for optimal use of currently available therapies in unresectable metastatic CRC are discussed, the evolving role of predictive and prognostic molecular markers is assessed, and current concepts and issues in the treatment of resectable metastatic CRC are described. Please be sure to view the accompanying (PDF) file or full CME/CE information. In this CME/CE activity, experts in oncology highlight latest evidence in advanced/metastatic colorectal cancer (CRC). Latest efficacy and safety data on targeted therapies are reviewed, strategies for optimal use of currently available therapies in unresectable metastatic CRC are discussed, the evolving role of predictive and prognostic molecular markers is assessed, and current concepts and issues in the treatment of resectable metastatic CRC are described. http://podcast.peerviewpress.com/oncology/PA04432FCs469.mp3 http://podcast.peerviewpress.com/oncology/PA04432FCs469.mp3 Fri, 11 Apr 2008 09:07:48 -0400 Science no 00:18:29 mCRC, EGFR, KRAS, ASCO-GI, FOLFIRI, oxaliplatin, BRiTE PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA04432FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA04423FCCMEinfo.pdf Fri, 11 Apr 2008 09:07:47 -0400 Science no 00:00:00 mCRC, EGFR, KRAS, ASCO-GI, FOLFIRI, oxaliplatin, BRiTE PeerView Press In this activity, experts in breast cancer discuss new data on targeted therapies in early stage and advanced/metastatic breast cancer. Please be sure to view the accompanying (PDF) file or full CME/CE information. In this activity, experts in breast cancer discuss new data on targeted therapies in early stage and advanced/metastatic breast cancer. http://podcast.peerviewpress.com/oncology/PA04112FCs450.mp3 http://podcast.peerviewpress.com/oncology/PA04112FCs450.mp3 Tue, 01 Apr 2008 11:49:02 -0400 Science no 00:41:08 HER2, SABCS, topo II, anthracycline, trastuzumab, recurrence score, bevacizumab PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA04112FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA04112FCCMEinfo.pdf Tue, 01 Apr 2008 11:48:02 -0400 Science no 00:00:00 HER2, SABCS, topo II, anthracycline, trastuzumab, recurrence score, bevacizumab PeerView Press In this case-based educational program, experts will discuss how to optimally use angiogensis inhibitors in treatment of advanced lung and colorectal malignancies, and use patient scenarios to illustrate how to manage common adverse effects in patients with these tumors receiving anti-VEGF therapy. Please be sure to view the accompanying (PDF) file or full CME/CE information. In this case-based educational program, experts will discuss how to optimally use angiogensis inhibitors in treatment of advanced lung and colorectal malignancies, and use patient scenarios to illustrate how to manage common adverse effects in patients with these tumors receiving anti-VEGF therapy. http://podcast.peerviewpress.com/oncology/PA03473FC2p125.mp3 http://podcast.peerviewpress.com/oncology/PA03473FC2p125.mp3 Wed, 26 Mar 2008 16:18:11 -0400 Science no 00:27:34 NSCLC, CRC, VEGF, antiangiogenesis, bevacizumab, oxaliplatin, liver metastases PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03473FC2CMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA03473FC2CMEinfo.pdf Wed, 26 Mar 2008 16:17:13 -0400 Science no 00:00:00 NSCLC, CRC, VEGF, antiangiogenesis, bevacizumab, oxaliplatin, liver metastases PeerView Press In this activity, an expert in breast cancer highlights latest clinical trial data in breast cancer, focusing on the role of chemotherapy in early stage and advanced breast cancer in the context of a move towards more individualized therapy. Please be sure to view the accompanying (PDF) file or full CME/CE information. In this activity, an expert in breast cancer highlights latest clinical trial data in breast cancer, focusing on the role of chemotherapy in early stage and advanced breast cancer in the context of a move towards more individualized therapy. http://podcast.peerviewpress.com/oncology/PA04309FCn178.mp3 http://podcast.peerviewpress.com/oncology/PA04309FCn178.mp3 Mon, 17 Mar 2008 16:53:37 -0400 Science no 00:23:58 Chemotherapy, HER2, trastuzumab, anthracycline, recurrence score, SABCS 2007, cytotoxics PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA04309FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA04309FCCMEinfo.pdf Mon, 17 Mar 2008 16:53:33 -0400 Science no 00:00:00 Chemotherapy, HER2, trastuzumab, anthracycline, recurrence score, SABCS 2007, cytotoxics PeerView Press In this program, an expert will discuss clinical scenarios to illustrate how to optimally manage patients with metastatic colorectal cancer, with a specific focus on use of molecularly targeted biologic agents in the context of other available therapies. Please be sure to view the accompanying (PDF) file or full CME/CE information. In this program, an expert will discuss clinical scenarios to illustrate how to optimally manage patients with metastatic colorectal cancer, with a specific focus on use of molecularly targeted biologic agents in the context of other available therapies. http://podcast.peerviewpress.com/oncology/PA03760FC1p121.mp3 http://podcast.peerviewpress.com/oncology/PA03760FC1p121.mp3 Fri, 14 Mar 2008 16:33:28 -0400 Science no 00:26:59 mCRC, systemic chemotherapy, FOLFOX, FOLFIRI, CAPOX, bevacizumab, oxaliplatin, 5-FU, leucovorin, EGFR, cetuximab PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03760FC1CMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA03760FC1CMEinfo.pdf Fri, 14 Mar 2008 16:32:28 -0400 Science no 00:00:00 mCRC, systemic chemotherapy, FOLFOX, FOLFIRI, CAPOX, bevacizumab, oxaliplatin, 5-FU, leucovorin, EGFR, cetuximab PeerView Press In this CME activity, experts provide an update on the current status and future directions in HER2 testing in breast cancer. Through an interactive discussion, the importance of accurate HER2 testing and the role of HER2 status as a predictive factor for HER2-targeted therapies are emphasized, current methods for HER2 testing and their benefits and limitations are assessed, and key recommendations for the latest ASCO-CAP HER2 testing guidelines are summarized. Furthermore, the experts describe some of the new molecular diagnostics, including multigene arrays, which are showing promise as better tools for determining HER2 status and predicting benefit from HER2-directed therapies. Please be sure to view the accompanying (PDF) file or full CME/CE information. In this CME activity, experts provide an update on the current status and future directions in HER2 testing in breast cancer. Through an interactive discussion, the importance of accurate HER2 testing and the role of HER2 status as a predictive factor for HER2-targeted therapies are emphasized, current methods for HER2 testing and their benefits and limitations are assessed, and key recommendations for the latest ASCO-CAP HER2 testing guidelines are summarized. Furthermore, the experts describe some of the new molecular diagnostics, including multigene arrays, which are showing promise as better tools for determining HER2 status and predicting benefit from HER2-directed therapies. http://podcast.peerviewpress.com/oncology/PA03994FCe008.mp3 http://podcast.peerviewpress.com/oncology/PA03994FCe008.mp3 Thu, 21 Feb 2008 10:55:05 -0500 Science no 00:34:26 HER2, trastuzumab, breast cancer, FISH, IHC, immunohistochemistry, array, immunostain, cytology, HER2/CEP 17 PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03994FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA03994FCCMEinfo.pdf Thu, 21 Feb 2008 10:54:06 -0500 Science no 00:00:00 HER2, trastuzumab, breast cancer, FISH, IHC, immunohistochemistry, array, immunostain, cytology, HER2/CEP 17 PeerView Press In this activity, experts in breast cancer discuss the optimal use of angiogenesis inhibitors. Recent clinical trial data on angiogenesis inhibitors are assessed; answers to common questions regarding the role of these agents are addressed; and patient scenarios are used to illustrate how to integrate anti-VEGF therapy into routine patient care. Please be sure to view the accompanying (PDF) file or full CME/CE information. In this activity, experts in breast cancer discuss the optimal use of angiogenesis inhibitors. Recent clinical trial data on angiogenesis inhibitors are assessed; answers to common questions regarding the role of these agents are addressed; and patient scenarios are used to illustrate how to integrate anti-VEGF therapy into routine patient care. http://podcast.peerviewpress.com/oncology/PA03775FC2r349.mp3 http://podcast.peerviewpress.com/oncology/PA03775FC2r349.mp3 Mon, 18 Feb 2008 11:23:57 -0500 Science no 00:34:08 Angiogenesis, breast cancer, VEGF, HER2, ER, paclitaxel, zolendronate, bevacizumab, E2100, case studies, ECOG, toxicities, capecitabine, first-line treatment, targeted agents, docetaxel, axitinib, trastuzumab, progression-free survival, PFS PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03775FC2CMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA03775FC2CMEinfo.pdf Mon, 18 Feb 2008 11:22:56 -0500 Science no 00:00:00 Angiogenesis, breast cancer, VEGF, HER2, ER, paclitaxel, zolendronate, bevacizumab, E2100, case studies, ECOG, toxicities, capecitabine, first-line treatment, targeted agents, docetaxel, axitinib, trastuzumab, progression-free survival, PFS PeerView Press In this CME activity, experts in the treatment of CML and Ph+ acute lymphoblastic leukemia discuss recent data on the role of targeted agents in the treatment of these diseases. An emphasis is placed on the second generation of targeted agents that are available for treatment of patients who develop imatinib resistance or intolerance. The mechanisms for developing resistance are also reviewed. Please be sure to view the accompanying (PDF) file or full CME/CE information. In this CME activity, experts in the treatment of CML and Ph+ acute lymphoblastic leukemia discuss recent data on the role of targeted agents in the treatment of these diseases. An emphasis is placed on the second generation of targeted agents that are available for treatment of patients who develop imatinib resistance or intolerance. The mechanisms for developing resistance are also reviewed. http://podcast.peerviewpress.com/oncology/PA03938FCe006.mp3 http://podcast.peerviewpress.com/oncology/PA03938FCe006.mp3 Thu, 14 Feb 2008 16:29:38 -0500 Science no 01:05:05 oncology, hematology, chronic myeloid leukemia CML, targeted therapies, resistance, tyrosine kinase inhibitors, chemotherapy, imatinib, dasatinib, nilotinib, mutations, bosutinib, MK-0457 PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03938FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA03938FCCMEinfo.pdf Thu, 14 Feb 2008 16:29:33 -0500 Science no 00:00:00 oncology, hematology, chronic myeloid leukemia CML, targeted therapies, resistance, tyrosine kinase inhibitors, chemotherapy, imatinib, dasatinib, nilotinib, mutations, bosutinib, MK-0457 PeerView Press In this program, an expert will discuss clinical scenarios to illustrate how to optimally manage patients with early stage colorectal cancer, with a focus on appropriate selection of adjuvant therapy for patients with stage II and III disease, and the emerging role of novel therapies and prognostic/predictive markers. Please be sure to view the accompanying (PDF) file or full CME/CE information. In this program, an expert will discuss clinical scenarios to illustrate how to optimally manage patients with early stage colorectal cancer, with a focus on appropriate selection of adjuvant therapy for patients with stage II and III disease, and the emerging role of novel therapies and prognostic/predictive markers. http://podcast.peerviewpress.com/oncology/PA03760FC2p128.mp3 http://podcast.peerviewpress.com/oncology/PA03760FC2p128.mp3 Mon, 11 Feb 2008 16:56:01 -0500 Science no 00:26:35 Colon, colorectal, oxaliplatin, 5-FU/LV, FOLFOX, FOLFOX4, capecitabine, fluoropyrimidine, CAPOX, bevacizumab, cetuximab, EGFR, capecitabine, FOLFOX6 PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03760FC2CMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA03760FC2CMEinfo.pdf Mon, 11 Feb 2008 16:55:56 -0500 Science no 00:00:00 Colon, colorectal, oxaliplatin, 5-FU/LV, FOLFOX, FOLFOX4, capecitabine, fluoropyrimidine, CAPOX, bevacizumab, cetuximab, EGFR, capecitabine, FOLFOX6 PeerView Press In this activity, an expert in breast cancer discusses goals and challenges in the management of metastatic breast cancer, and how these goals can be best met through individualized therapy. Please be sure to view the accompanying (PDF) file or full CME/CE information. In this activity, an expert in breast cancer discusses goals and challenges in the management of metastatic breast cancer, and how these goals can be best met through individualized therapy. http://podcast.peerviewpress.com/oncology/PA03916FCn172.mp3 http://podcast.peerviewpress.com/oncology/PA03916FCn172.mp3 Wed, 23 Jan 2008 15:53:13 -0500 Science no 00:22:32 Metastatic breast cancer, MBC, bevacizumab, anthracyclines, overall survival, progression-free survival, response rate, gemcitabine, paclitaxel, vinorelbine, ixabepilone, cytotoxic. PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03916FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA03916FCCMEinfo.pdf Wed, 23 Jan 2008 15:53:07 -0500 Science no 00:00:00 Metastatic breast cancer, MBC, bevacizumab, anthracyclines, overall survival, progression-free survival, response rate, gemcitabine, paclitaxel, vinorelbine, ixabepilone, cytotoxic. PeerView Press In this CME program, an expert in the treatment of renal cell carcinoma discusses advances in the use of targeted therapies in the management of this disease in a case-based format. Please be sure to view the accompanying (PDF) file or full CME/CE information. In this CME program, an expert in the treatment of renal cell carcinoma discusses advances in the use of targeted therapies in the management of this disease in a case-based format. http://podcast.peerviewpress.com/oncology/PA04017FCn174.mp3 http://podcast.peerviewpress.com/oncology/PA04017FCn174.mp3 Mon, 21 Jan 2008 16:55:48 -0500 Science no 00:14:18 renal cell carcinoma, renal cell cancer, RCC, metastatic RCC, advanced RCC, targeted therapies, tyrosine kinase inhibitors, TKIs, IL-2, sunitinib, sorafenib, bevacizumab, temsirolimus, IFN-α, Memorial Sloan-Kettering Cancer Center (MSKCC) system PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA04017FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA04017FCCMEinfo.pdf Mon, 21 Jan 2008 16:54:49 -0500 Science no 00:00:00 renal cell carcinoma, renal cell cancer, RCC, metastatic RCC, advanced RCC, targeted therapies, tyrosine kinase inhibitors, TKIs, IL-2, sunitinib, sorafenib, bevacizumab, temsirolimus, IFN-α, Memorial Sloan-Kettering Cancer Center (MSKCC) system PeerView Press In this CME activity, experts in the treatment of colorectal cancer present recent data on the efficacy and safety of targeted agents in the management of advanced disease. Strategies for integration of these agents into treatment plans are also highlighted. Please be sure to view the accompanying (PDF) file or full CME/CE information. In this CME activity, experts in the treatment of colorectal cancer present recent data on the efficacy and safety of targeted agents in the management of advanced disease. Strategies for integration of these agents into treatment plans are also highlighted. http://podcast.peerviewpress.com/oncology/PA04093FCs443.mp3 http://podcast.peerviewpress.com/oncology/PA04093FCs443.mp3 Thu, 20 Dec 2007 15:41:54 -0500 Science no 00:25:28 Biologics, mCRC, CRC, metastatic, colorectal, cancer, biologics, cytotoxic, panitumumab, erlotinib, bevacizumab, VEGF, EGRF PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA04093FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA04093FCCMEinfo.pdf Thu, 20 Dec 2007 15:41:48 -0500 Science no 00:00:00 Biologics, mCRC, CRC, metastatic, colorectal, cancer, biologics, cytotoxic, panitumumab, erlotinib, bevacizumab, VEGF, EGRF PeerView Press In this activity, experts review latest evidence on antiangiogenic therapies in breast cancer. Different ways to target angiogenesis in breast cancer are described, and recent data from studies evaluating angiogenesis inhibitors with cytotoxic and other targeted agents in breast cancer are discussed. Please be sure to view the accompanying (PDF) file or full CME/CE information. In this activity, experts review latest evidence on antiangiogenic therapies in breast cancer. Different ways to target angiogenesis in breast cancer are described, and recent data from studies evaluating angiogenesis inhibitors with cytotoxic and other targeted agents in breast cancer are discussed. http://podcast.peerviewpress.com/oncology/PA03775FC1r348.mp3 http://podcast.peerviewpress.com/oncology/PA03775FC1r348.mp3 Wed, 12 Dec 2007 15:59:46 -0500 Science no 00:31:20 Breast cancer, bevacizumab, trastuzumab, angiogenesis inhibition, antiangiogenic therapy, targeted therapy, biologics, VEGF, HER2 PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03775FC1CMECEinfo.pdf http://podcast.peerviewpress.com/oncology/PA03775FC1CMECEinfo.pdf Wed, 12 Dec 2007 15:59:43 -0500 Science no 00:00:00 Breast cancer, bevacizumab, trastuzumab, angiogenesis inhibition, antiangiogenic therapy, targeted therapy, biologics, VEGF, HER2 PeerView Press In this activity, experts will present an overview of key clinical data on antiangiogenic therapies in solid tumors and discuss practical aspects related to using these agents in routine patient care. Particular attention will be paid to adverse events associated with use of the anti-VEGF agents in colorectal, lung, and breast cancer, and recommendations for the management of common toxicities will be provided. Please be sure to view the accompanying (PDF) file or full CME/CE information. In this activity, experts will present an overview of key clinical data on antiangiogenic therapies in solid tumors and discuss practical aspects related to using these agents in routine patient care. Particular attention will be paid to adverse events associated with use of the anti-VEGF agents in colorectal, lung, and breast cancer, and recommendations for the management of common toxicities will be provided. http://podcast.peerviewpress.com/oncology/PA03473FC1r316.mp3 http://podcast.peerviewpress.com/oncology/PA03473FC1r316.mp3 Mon, 26 Nov 2007 17:18:19 -0500 Science no 00:53:21 Bevacizumab, angiogenisis, angiogenic therapy, VEGF, ECOG 4599, AVF2107, ECOG 3200, NO16966, FOLFOX, XELOX, ECOG 2100, sunitinib, AVOREN, EGFR PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03473FC1CMECEinfo.pdf http://podcast.peerviewpress.com/oncology/PA03473FC1CMECEinfo.pdf Mon, 26 Nov 2007 17:18:16 -0500 Science no 00:00:00 Bevacizumab, angiogenisis, angiogenic therapy, VEGF, ECOG 4599, AVF2107, ECOG 3200, NO16966, FOLFOX, XELOX, ECOG 2100, sunitinib, AVOREN, EGFR PeerView Press In this CME activity, an expert discusses optimal treatment of operable and inoperable pancreatic cancer based on relevant case scenarios. Please be sure to view the accompanying (PDF) file or full CME/CE information. In this CME activity, an expert discusses optimal treatment of operable and inoperable pancreatic cancer based on relevant case scenarios. http://podcast.peerviewpress.com/oncology/PA03788FCp126.mp3 http://podcast.peerviewpress.com/oncology/PA03788FCp126.mp3 Fri, 16 Nov 2007 16:33:08 -0500 Science no 00:34:11 Pancreatic cancer, pancreas, adjuvant chemotherapy, resectable, unresectable, operable, inoperable, targeted therapies, biologics, gemcitabine, bevacizumab, cetuximab, erlotinib PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03788FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA03788FCCMEinfo.pdf Fri, 16 Nov 2007 16:33:04 -0500 Science no 00:00:00 Pancreatic cancer, pancreas, adjuvant chemotherapy, resectable, unresectable, operable, inoperable, targeted therapies, biologics, gemcitabine, bevacizumab, cetuximab, erlotinib PeerView Press This case-based program describes three clinical situations illustrating the identification and management of patients with cancer and risk for VTE. Please be sure to view the accompanying (PDF) file or full CME/CE information. This case-based program describes three clinical situations illustrating the identification and management of patients with cancer and risk for VTE. http://podcast.peerviewpress.com/oncology/PA03702FCp129.mp3 http://podcast.peerviewpress.com/oncology/PA03702FCp129.mp3 Thu, 15 Nov 2007 17:04:38 -0500 Science no 00:50:25 Venous thromboembolism, cancer, deep vein thrombosis, pulmonary embolism, low molecular weight heparin, anticoagulants, Thrombolytic therapy, heparin, warfarin, breast cancer, prostate cancer, colorectal cancer, surgery PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03702FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA03702FCCMEinfo.pdf Thu, 15 Nov 2007 17:04:37 -0500 Science no 00:00:00 Venous thromboembolism, cancer, deep vein thrombosis, pulmonary embolism, low molecular weight heparin, anticoagulants, Thrombolytic therapy, heparin, warfarin, breast cancer, prostate cancer, colorectal cancer, surgery PeerView Press In this CME activity, an expert discusses treatment of advanced NSCLC, with a main focus on optimal integration of targeted agents into standard therapy for this disease. Please be sure to view the accompanying (PDF) file or full CME/CE information. In this CME activity, an expert discusses treatment of advanced NSCLC, with a main focus on optimal integration of targeted agents into standard therapy for this disease. http://podcast.peerviewpress.com/oncology/PA03645FCp123.mp3 http://podcast.peerviewpress.com/oncology/PA03645FCp123.mp3 Fri, 26 Oct 2007 15:00:35 -0400 Science no 00:27:49 Lung cancer, NSCLC, targeted therapy, biologics, VEGF, EGFR, erlotinib, Tarceva, bevacizumab, Avastin, sunitinib, sorafenib, gefitinib PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03645FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA03645FCCMEinfo.pdf Fri, 26 Oct 2007 15:00:35 -0400 Science no 00:00:00 Lung cancer, NSCLC, targeted therapy, biologics, VEGF, EGFR, erlotinib, Tarceva, bevacizumab, Avastin, sunitinib, sorafenib, gefitinib PeerView Press In this CME activity, an expert discusses treatment of early stage HER2-positive breast cancer based on relevant case scenarios, with a main focus on optimal use of HER2-targeted therapy in the context of other available treatment options. Please be sure to view the accompanying (PDF) file or full CME/CE information. In this CME activity, an expert discusses treatment of early stage HER2-positive breast cancer based on relevant case scenarios, with a main focus on optimal use of HER2-targeted therapy in the context of other available treatment options. http://podcast.peerviewpress.com/oncology/PA03486FCp120.mp3 http://podcast.peerviewpress.com/oncology/PA03486FCp120.mp3 Thu, 18 Oct 2007 15:59:50 -0400 Science no 00:26:02 HER2, breast cancer, HER2-targeted therapy, HER2 testing, trastuzumab, Herceptin, NSABP B31, NCCTG 9831, HERA, BCIRG 006 PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03486FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA03486FCCMEinfo.pdf Thu, 18 Oct 2007 15:59:43 -0400 Science no 00:00:00 HER2, breast cancer, HER2-targeted therapy, HER2 testing, trastuzumab, Herceptin, NSABP B31, NCCTG 9831, HERA, BCIRG 006 PeerView Press In this activity, experts present current data on antiangiogenic therapies in metastatic breast cancer (MBC). Clinical relevance of the endpoints used with cytostatic targeted agents and cytotoxic chemotherapeutics in MBC is evaluated. Recent efficacy and safety data from studies evaluating antiangiogenic therapies in advanced disease are summarized and interpreted, and practical recommendations for optimal integration of angiogenesis inhibitors into the treatment of MBC are provided. Please be sure to view the accompanying (PDF) file or full CME/CE information. In this activity, experts present current data on antiangiogenic therapies in metastatic breast cancer (MBC). Clinical relevance of the endpoints used with cytostatic targeted agents and cytotoxic chemotherapeutics in MBC is evaluated. Recent efficacy and safety data from studies evaluating antiangiogenic therapies in advanced disease are summarized and interpreted, and practical recommendations for optimal integration of angiogenesis inhibitors into the treatment of MBC are provided. http://podcast.peerviewpress.com/oncology/PA03499FCr330.mp3 http://podcast.peerviewpress.com/oncology/PA03499FCr330.mp3 Thu, 27 Sep 2007 10:14:51 -0400 Science no 00:31:29 Breast cancer, MBC, VEGF, antiangiogenic, ECOG 2100, bevacizumab, Avastin, angiogenesis inhibitors, tyrosine kinase inhibitors PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03499FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA03499FCCMEinfo.pdf Thu, 27 Sep 2007 10:14:50 -0400 Science no 00:00:00 Breast cancer, MBC, VEGF, antiangiogenic, ECOG 2100, bevacizumab, Avastin, angiogenesis inhibitors, tyrosine kinase inhibitors PeerView Press In this activity, experts in the treatment of lung cancer present the most current data on molecularly targeted agents in the treatment of NSCLC. Efficacy and safety of anti-VEGF, anti-EGFR, and other novel targeted therapies will be discussed. The experts will also focus on the evolving role of predictive and prognostic markers and the importance of developing such tools that could assist clinicians in selecting optimal therapy for each individual patient with lung cancer. Please be sure to view the accompanying (PDF) file or full CME/CE information. In this activity, experts in the treatment of lung cancer present the most current data on molecularly targeted agents in the treatment of NSCLC. Efficacy and safety of anti-VEGF, anti-EGFR, and other novel targeted therapies will be discussed. The experts will also focus on the evolving role of predictive and prognostic markers and the importance of developing such tools that could assist clinicians in selecting optimal therapy for each individual patient with lung cancer. http://podcast.peerviewpress.com/oncology/PA03774FC2s410.mp3 http://podcast.peerviewpress.com/oncology/PA03774FCs410.mp3 Tue, 25 Sep 2007 12:53:57 -0400 Science no 00:39:34 Lung cancer, NSCLC, targeted therapy, biologics, VEGF, EGFR, erlotinib, Tarceva, bevacizumab, Avastin, ASCO, sunitinib, sorafenib, gefitinib PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03774FC2CMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA03774FC2CMEinfo.pdf Tue, 25 Sep 2007 12:52:54 -0400 Science no 00:00:00 Lung cancer, NSCLC, targeted therapy, biologics, VEGF, EGFR, erlotinib, Tarceva, bevacizumab, Avastin, ASCO, sunitinib, sorafenib, gefitinib PeerView Press In this program, experts present up-to-date information on treatment of advanced or metastatic NSCLC. Options for first-, second-, and third-line treatment are discussed, and factors that influence treatment decisions in these settings are assessed. Please be sure to view the accompanying (PDF) file or full CME/CE information. In this program, experts present up-to-date information on treatment of advanced or metastatic NSCLC. Options for first-, second-, and third-line treatment are discussed, and factors that influence treatment decisions in these settings are assessed. http://podcast.peerviewpress.com/oncology/PA03912FCs323.mp3 http://podcast.peerviewpress.com/oncology/PA03912FCs323.mp3 Thu, 20 Sep 2007 16:04:06 -0400 Science no 00:23:50 NSCLC, lung cancer, chemotherapy, targeted therapy, alternative treatments, gemcitabine, pemetrexed, bevacizumab, erlotinib, treatment selection, individualized treatment, ASCO, NCCN PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03912FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA03912FCCMEinfo.pdf Thu, 20 Sep 2007 16:04:02 -0400 Science no 00:00:00 NSCLC, lung cancer, chemotherapy, targeted therapy, alternative treatments, gemcitabine, pemetrexed, bevacizumab, erlotinib, treatment selection, individualized treatment, ASCO, NCCN PeerView Press In this CME activity, experts in lung cancer discuss the current and evolving role of molecularly targeted therapies in NSCLC. Clinical data on anti-VEGF and anti-EGFR therapies are assessed, and practical considerations for optimal integration of these agents into standard treatment for NSCLC are discussed. Unanswered questions regarding the role of targeted therapies and future research directions are described as well. Please be sure to view the accompanying (PDF) file or full CME/CE information. In this CME activity, experts in lung cancer discuss the current and evolving role of molecularly targeted therapies in NSCLC. Clinical data on anti-VEGF and anti-EGFR therapies are assessed, and practical considerations for optimal integration of these agents into standard treatment for NSCLC are discussed. Unanswered questions regarding the role of targeted therapies and future research directions are described as well. http://podcast.peerviewpress.com/oncology/PA03774FC1r315.mp3 http://podcast.peerviewpress.com/oncology/PA03774FC1r315.mp3 Wed, 12 Sep 2007 11:00:59 -0400 Science no 00:36:58 Lung cancer, NSCLC, targeted therapy, biologics, VEGF, EGFR, erlotinib, bevacizumab, Avastin PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03774FC1CMECEinfo.pdf http://podcast.peerviewpress.com/oncology/PA03774FC1CMECEinfo.pdf Wed, 12 Sep 2007 11:00:35 -0400 Science no 00:00:00 Lung cancer, NSCLC, targeted therapy, biologics, VEGF, EGFR, erlotinib, bevacizumab, Avastin PeerView Press In this CME activity, experts in the treatment of hepatocellular carcinoma (HCC) discuss recent data on the efficacy and safety of emerging biologically driven agents in this condition. The recent data on staging systems and classification systems for HCC are also reviewed and the molecular targets in HCC are discussed. Please be sure to view the accompanying (PDF) file or full CME/CE information. In this CME activity, experts in the treatment of hepatocellular carcinoma (HCC) discuss recent data on the efficacy and safety of emerging biologically driven agents in this condition. The recent data on staging systems and classification systems for HCC are also reviewed and the molecular targets in HCC are discussed. http://podcast.peerviewpress.com/oncology/PA04009FCs413.mp3 http://podcast.peerviewpress.com/oncology/PA04009FCs413.mp3 Fri, 24 Aug 2007 18:35:21 -0400 Science no 00:38:27 hepatocellular carcinoma, advanced hepatocellular carcinoma, HCC, targeted agents, biologic agents, staging systems, hepatitis B, hepatitis, C, cirrhosis, transplantation, chemotherapy, sorafenib, cetuximab, sunitinib, bevacizumab, erlotinib PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA04009FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA04009FCCMEinfo.pdf Fri, 24 Aug 2007 18:34:38 -0400 Science no 00:00:00 hepatocellular carcinoma, advanced hepatocellular carcinoma, HCC, targeted agents, biologic agents, staging systems, hepatitis B, hepatitis, C, cirrhosis, transplantation, chemotherapy, sorafenib, cetuximab, sunitinib, bevacizumab, erlotinib PeerView Press In this panel discussion, experts present up-to-date data on antiangiogenic therapies in breast cancer. Recent clinical data on antiangiogenic therapy in metastatic breast cancer are reviewed, and implications for clinical practice and research are discussed. The potential benefits of targeting multiple pathways in breast cancer, by using a combination of antiangiogenic and other biologic agents or novel multitargeted therapies with antiangiogenic properties, are described. As well, strategies for optimal integration of antiangiogenic agents into treatment of breast cancer in the context of other cytotoxic and biologic therapies are discussed. Please be sure to view the accompanying (PDF) file or full CME/CE information. In this panel discussion, experts present up-to-date data on antiangiogenic therapies in breast cancer. Recent clinical data on antiangiogenic therapy in metastatic breast cancer are reviewed, and implications for clinical practice and research are discussed. The potential benefits of targeting multiple pathways in breast cancer, by using a combination of antiangiogenic and other biologic agents or novel multitargeted therapies with antiangiogenic properties, are described. As well, strategies for optimal integration of antiangiogenic agents into treatment of breast cancer in the context of other cytotoxic and biologic therapies are discussed. http://podcast.peerviewpress.com/oncology/PA03257FC3e004.mp3 http://podcast.peerviewpress.com/oncology/PA03257FC3e004.mp3 Thu, 23 Aug 2007 09:27:50 -0400 Science no 00:46:02 Breast cancer, angiogenesis inhibition, antiangiogenic therapy, VEGF, HER2, bevacizumab, trastuzumab, sunitinib, axitinib, targeted therapy, biologics, SABCS, ASCO PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03257FC3CMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA03257FC3CMEinfo.pdf Thu, 23 Aug 2007 09:27:11 -0400 Science no 00:00:00 Breast cancer, angiogenesis inhibition, antiangiogenic therapy, VEGF, HER2, bevacizumab, trastuzumab, sunitinib, axitinib, targeted therapy, biologics, SABCS, ASCO PeerView Press In this CME activity, experts in the treatment of advanced renal cell carcinoma discuss recent data on the efficacy and safety of current and emerging targeted agents and combinations in this condition. Dosing concerns and patient selection are also highlighted. Please be sure to view the accompanying (PDF) file or full CME/CE information. In this CME activity, experts in the treatment of advanced renal cell carcinoma discuss recent data on the efficacy and safety of current and emerging targeted agents and combinations in this condition. Dosing concerns and patient selection are also highlighted. http://podcast.peerviewpress.com/oncology/PA03777FCs407.mp3 http://podcast.peerviewpress.com/oncology/PA03777FCs407.mp3 Wed, 22 Aug 2007 15:32:29 -0400 Science no 00:30:24 renal cell carcinoma, renal cell cancer, RCC, metastatic RCC, advanced RCC, targeted therapies, tyrosine kinase inhibitors, TKIs, IL-2, sunitinib, sorafenib, bevacizumab, temsirolimus, erlotinib, IFN-α, UCLA Integrated Staging System, Von Hippel Lindau PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03777FCs407CMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA03777FCs407CMEinfo.pdf Wed, 22 Aug 2007 15:32:17 -0400 Science no 00:00:00 renal cell carcinoma, renal cell cancer, RCC, metastatic RCC, advanced RCC, targeted therapies, tyrosine kinase inhibitors, TKIs, IL-2, sunitinib, sorafenib, bevacizumab, temsirolimus, erlotinib, IFN-α, UCLA Integrated Staging System, Von Hippel Lindau PeerView Press In this activity, experts present up-to-date data on molecularly targeted therapies in metastatic colorectal cancer (CRC). The impact and expanding role of targeted agents in the treatment of metastatic CRC are reviewed, and latest efficacy and safety data biologics in the context of other available therapies, as well as the potential implications for clinical practice, are assessed. Furthermore, important clinical questions/issues related to treatment of advanced disease are discussed, and strategies for optimal use of all the available agents in the treatment of patients with metastatic CRC are proposed. Please be sure to view the accompanying (PDF) file or full CME/CE information. In this activity, experts present up-to-date data on molecularly targeted therapies in metastatic colorectal cancer (CRC). The impact and expanding role of targeted agents in the treatment of metastatic CRC are reviewed, and latest efficacy and safety data biologics in the context of other available therapies, as well as the potential implications for clinical practice, are assessed. Furthermore, important clinical questions/issues related to treatment of advanced disease are discussed, and strategies for optimal use of all the available agents in the treatment of patients with metastatic CRC are proposed. http://podcast.peerviewpress.com/oncology/PA03759FCs409.mp3 http://podcast.peerviewpress.com/oncology/PA03759FCs409_2.mp3 Wed, 15 Aug 2007 16:45:44 -0400 Science no 00:31:45 Colorectal cancer, targeted therapy, biologic therapy, bevacizumab, Avastin, cetuximab, Erbitux, panitumumab, vascular endothelial growth factor, VEGF, EGFR, epidermal growth factor receptor, ASCO 2007 PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03759FCs409.pdf http://podcast.peerviewpress.com/oncology/PA03759FCs409.pdf Wed, 15 Aug 2007 16:45:16 -0400 Science no 00:00:00 Colorectal cancer, targeted therapy, biologic therapy, bevacizumab, Avastin, cetuximab, Erbitux, panitumumab, vascular endothelial growth factor, VEGF, EGFR, epidermal growth factor receptor, ASCO 2007 PeerView Press In this CME activity, experts provide an overview of recent progress in the treatment of breast cancer, focusing on the evolving role of molecularly targeted therapies. Current clinical data on HER2- and VEGF-targeted agents in the treatment of early stage and metastatic breast cancer are summarized, and the clinical implications of these data are assessed. Furthermore, clinical issues related to optimal use of HER2- and VEGF-targeted therapies in the treatment of breast cancer are discussed. Lastly, some of the new and ongoing studies evaluating the targeted agents are reviewed, as well as novel molecularly targeted therapies currently under investigation in breast cancer. Please be sure to view the accompanying (PDF) file or full CME/CE information. In this CME activity, experts provide an overview of recent progress in the treatment of breast cancer, focusing on the evolving role of molecularly targeted therapies. Current clinical data on HER2- and VEGF-targeted agents in the treatment of early stage and metastatic breast cancer are summarized, and the clinical implications of these data are assessed. Furthermore, clinical issues related to optimal use of HER2- and VEGF-targeted therapies in the treatment of breast cancer are discussed. Lastly, some of the new and ongoing studies evaluating the targeted agents are reviewed, as well as novel molecularly targeted therapies currently under investigation in breast cancer. http://podcast.peerviewpress.com/oncology/PA03257FC5r338.mp3 http://podcast.peerviewpress.com/oncology/PA03257FC5r338.mp3 Fri, 03 Aug 2007 14:03:29 -0400 Science no 00:54:34 Breast cancer, VEGF, HER2, bevacizumab, trastuzumab, lapatinib, angiogenesis inhibition, antiangiogenic therapy, targeted therapy, biologics, SABCS, ASCO PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03257FC5CMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA03257FC5CMEinfo.pdf Fri, 03 Aug 2007 14:03:13 -0400 Science no 00:00:00 Breast cancer, VEGF, HER2, bevacizumab, trastuzumab, lapatinib, angiogenesis inhibition, antiangiogenic therapy, targeted therapy, biologics, SABCS, ASCO PeerView Press In this CME activity, experts in the management of CML discuss current and emerging targeted therapies for this condition. Mechanisms for the development and monitoring of resistance are also reviewed. Please be sure to view the accompanying (PDF) file or full CME/CE information. In this CME activity, experts in the management of CML discuss current and emerging targeted therapies for this condition. Mechanisms for the development and monitoring of resistance are also reviewed. http://podcast.peerviewpress.com/oncology/PA03826FCr320.mp3 http://podcast.peerviewpress.com/oncology/PA03826FCr320.mp3 Thu, 12 Jul 2007 14:55:12 -0400 Science no 00:25:19 oncology, hematology, acute lymphocytic leukaemia, chronic myeloid leukaemia, CML, targeted therapies, tyrosine kinase inhibitors, chemotherapy, imatinib, dasatinib, nilotinib, resistance monitoring, mutations, bosutinib, MK-0457 PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03826FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA03826FCCMEinfo.pdf Thu, 12 Jul 2007 14:54:55 -0400 Science no 00:00:00 oncology, hematology, acute lymphocytic leukaemia, chronic myeloid leukaemia, CML, targeted therapies, tyrosine kinase inhibitors, chemotherapy, imatinib, dasatinib, nilotinib, resistance monitoring, mutations, bosutinib, MK-0457 PeerView Press In this CME activity, experts provide an overview of recent progress, current challenges, and future opportunities in the treatment of breast cancer. The evolving role of molecular markers in making treatment decisions for patients with breast cancer is summarized. Evidence-based recommendations regarding treatment strategies for patients with breast cancer based on several different clinical case scenarios are discussed. Safety profiles of the taxanes and current options for management of febrile neutropenia in patients receiving taxane-based therapy are reviewed. Ongoing and new trials in the adjuvant and neoadjuvant settings aiming to determine the optimal way to use available cytotoxic and biologic agents in early stage breast cancer are described. And finally, the potential role of some of the novel cytotoxic and molecularly targeted therapies currently under investigation in breast cancer is discussed. Please be sure to view the accompanying (PDF) file or full CME/CE information. In this CME activity, experts provide an overview of recent progress, current challenges, and future opportunities in the treatment of breast cancer. The evolving role of molecular markers in making treatment decisions for patients with breast cancer is summarized. Evidence-based recommendations regarding treatment strategies for patients with breast cancer based on several different clinical case scenarios are discussed. Safety profiles of the taxanes and current options for management of febrile neutropenia in patients receiving taxane-based therapy are reviewed. Ongoing and new trials in the adjuvant and neoadjuvant settings aiming to determine the optimal way to use available cytotoxic and biologic agents in early stage breast cancer are described. And finally, the potential role of some of the novel cytotoxic and molecularly targeted therapies currently under investigation in breast cancer is discussed. http://podcast.peerviewpress.com/oncology/PA03727FCr296.mp3 http://podcast.peerviewpress.com/oncology/PA03727FCr296.mp3 Thu, 21 Jun 2007 15:39:00 -0400 Science no 00:45:23 Breast cancer, molecular markers, taxanes, paclitaxel, Taxol, docetaxel, Taxotere, chemotherapy, biologics, targeted therapies, febrile neutropenia, growth factors, G-CSF PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03727FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA03727FCCMEinfo.pdf Thu, 21 Jun 2007 15:38:47 -0400 Science no 00:00:00 Breast cancer, molecular markers, taxanes, paclitaxel, Taxol, docetaxel, Taxotere, chemotherapy, biologics, targeted therapies, febrile neutropenia, growth factors, G-CSF PeerView Press In this CME/CE activity, experts in the treatment of CML present recent data on the efficacy and safety of new and emerging agents used in the treatment of this disease. Molecular monitoring and development of resistance are also highlighted. Please be sure to view the accompanying (PDF) file or full CME/CE information. In this CME/CE activity, experts in the treatment of CML present recent data on the efficacy and safety of new and emerging agents used in the treatment of this disease. Molecular monitoring and development of resistance are also highlighted. http://podcast.peerviewpress.com/oncology/PA02183FC2r309.mp3 http://podcast.peerviewpress.com/oncology/PA02183FC2r309.mp3 Wed, 20 Jun 2007 17:03:58 -0400 Science no 00:52:31 chronic myeloid leukemia, imatinib, dasatinib, nilotinib, SKI-606, MK-0457, CML, tyrosine kinase inhibitors, targeted therapies, BCR-ABL, Src kinase, chronic phase, accelerated phase, blast crisis, cytogenetic response, hematologic response PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA02183FC2CMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA02183FC2CMEinfo.pdf Wed, 20 Jun 2007 17:03:30 -0400 Science no 00:00:00 chronic myeloid leukemia, imatinib, dasatinib, nilotinib, SKI-606, MK-0457, CML, tyrosine kinase inhibitors, targeted therapies, BCR-ABL, Src kinase, chronic phase, accelerated phase, blast crisis, cytogenetic response, hematologic response PeerView Press In this activity, expert oncologists discuss the current, evidence-based use of endocrine therapy in postmenopausal women with early breast cancer, including the rationales for upfront or sequential use of aromatase inhibitors (AIs) after tamoxifen. In addition, emerging evidence for the use of AIs in initially premenopausal women with breast cancer is presented. Please be sure to view the accompanying (PDF) file or full CME/CE information. In this activity, expert oncologists discuss the current, evidence-based use of endocrine therapy in postmenopausal women with early breast cancer, including the rationales for upfront or sequential use of aromatase inhibitors (AIs) after tamoxifen. In addition, emerging evidence for the use of AIs in initially premenopausal women with breast cancer is presented. http://podcast.peerviewpress.com/oncology/PA03651FCr297.mp3 http://podcast.peerviewpress.com/oncology/PA03651FCr297.mp3 Tue, 05 Jun 2007 14:11:07 -0400 Science no 00:22:09 Anastrozole, Aromatase inhibitor (AI), Bone-mineral density (BMD), Breast cancer, Exemestane, Letrozole, Ovarian suppression, Tamoxifen PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03651FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA03651FCCMEinfo.pdf Tue, 05 Jun 2007 14:10:38 -0400 Science no 00:00:00 Anastrozole, Aromatase inhibitor (AI), Bone-mineral density (BMD), Breast cancer, Exemestane, Letrozole, Ovarian suppression, Tamoxifen PeerView Press In this CME/CE activity, experts in the treatment of acute lymphocytic leukemia (ALL) and chronic myeloid leukemia (CML) review recent data on efficacy and safety of current and emerging targeted therapies in the treatment of these conditions. Recent data on management issues and strategies are also discussed. Please be sure to view the accompanying (PDF) file or full CME/CE information. In this CME/CE activity, experts in the treatment of acute lymphocytic leukemia (ALL) and chronic myeloid leukemia (CML) review recent data on efficacy and safety of current and emerging targeted therapies in the treatment of these conditions. Recent data on management issues and strategies are also discussed. http://podcast.peerviewpress.com/oncology/PA03164FCs327.mp3 http://podcast.peerviewpress.com/oncology/PA03164FCs327.mp3 Mon, 07 May 2007 15:40:12 -0400 Science no 00:40:36 oncology, hematology, acute lymphocytic leukaemia, chronic myeloid leukemia CML, ALL, targeted therapies, tyrosine kinase inhibitors, chemotherapy, imatinib, dasatinib, nilotinib, American Society of Hematology Meeting, ASH, mutations, bosutinib, MK-0457 PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03164FCCMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA03164FCCMEinfo.pdf Mon, 07 May 2007 15:39:46 -0400 Science no 00:00:00 oncology, hematology, acute lymphocytic leukaemia, chronic myeloid leukemia CML, ALL, targeted therapies, tyrosine kinase inhibitors, chemotherapy, imatinib, dasatinib, nilotinib, American Society of Hematology Meeting, ASH, mutations, bosutinib, MK-0457 PeerView Press This CME activity reviews current perspectives on antiangiogenic therapy in lung cancer. Data from clinical trials evaluating antiangiogenic agents in the treatment of NSCLC are summarized, and clinical issues related to using antiangiogenic therapy in the management of patients with lung cancer, as well as unanswered questions and future research directions, are discussed. Please be sure to view the accompanying (PDF) file or full CME/CE information. This CME activity reviews current perspectives on antiangiogenic therapy in lung cancer. Data from clinical trials evaluating antiangiogenic agents in the treatment of NSCLC are summarized, and clinical issues related to using antiangiogenic therapy in the management of patients with lung cancer, as well as unanswered questions and future research directions, are discussed. http://podcast.peerviewpress.com/oncology/PA03070FC4r279.mp3 http://podcast.peerviewpress.com/oncology/PA03070FC4r279.mp3 Tue, 24 Apr 2007 10:02:08 -0400 Science no 00:33:00 NSCLC, targeted therapy, biologics, VEGF, antiangiogenic, ECOG 4599, angiogenesis inhibition, bevacizumab, Avastin, EGFR, erlotinib, Tarceva, sunitinib, sorafenib, ZD6474 PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03070FC4CMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA03070FC4CMEinfo.pdf Tue, 24 Apr 2007 10:01:37 -0400 Science no 00:00:00 NSCLC, targeted therapy, biologics, VEGF, antiangiogenic, ECOG 4599, angiogenesis inhibition, bevacizumab, Avastin, EGFR, erlotinib, Tarceva, sunitinib, sorafenib, ZD6474 PeerView Press In this activity, experts in oncology review the evolving role of cytotoxic and molecularly targeted agents in the treatment of metastatic colorectal cancer (mCRC). Clinical data from studies evaluating the efficacy and safety of currently recommended chemotherapy combinations, as well as VEGF- and EGFR-targeted therapies, are reviewed and evaluated. Practical issues related to optimal use of these therapies in the management of patients with mCRC are also discussed. Please be sure to view the accompanying (PDF) file or full CME/CE information. In this activity, experts in oncology review the evolving role of cytotoxic and molecularly targeted agents in the treatment of metastatic colorectal cancer (mCRC). Clinical data from studies evaluating the efficacy and safety of currently recommended chemotherapy combinations, as well as VEGF- and EGFR-targeted therapies, are reviewed and evaluated. Practical issues related to optimal use of these therapies in the management of patients with mCRC are also discussed. http://podcast.peerviewpress.com/oncology/PA03256FC4s348.mp3 http://podcast.peerviewpress.com/oncology/PA03256FC4s348.mp3 Fri, 20 Apr 2007 15:11:28 -0400 Science no 00:35:55 Colorectal cancer, CRC, targeted therapy, biologic therapy, bevacizumab, Avastin, cetuximab, Erbitux, panitumumab, vascular endothelial growth factor, VEGF, EGFR, epidermal growth factor receptor, ASCO-GI PeerView Press Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/oncology/PA03256FC4CMEinfo.pdf http://podcast.peerviewpress.com/oncology/PA03256FC4CMEinfo.pdf Fri, 20 Apr 2007 15:11:10 -0400 Science no 00:00:00 Colorectal cancer, CRC, targeted therapy, biologic therapy, bevacizumab, Avastin, cetuximab, Erbitux, panitumumab, vascular endothelial growth factor, VEGF, EGFR, epidermal growth factor receptor, ASCO-GI PeerView Press In this CME/CE activity, experts in the treatment of squamous cell cancer of the head and neck (SCCHN) and non–small-cell lung cancer (NSCLC) discuss recent data on the efficacy of targeted therapies—alone and in combination with other medications—in the treatment of both of these cancers. Common adverse effects that can occur with these agents are reviewed and management strategies are discussed. Molecular testing in SCCHN and NSCLC is highlighted. Please be sure to view the accompanying (PDF) file or full CME/CE information. In this CME/CE activity, experts in the treatment of squamous cell cancer of the head and neck (SCCHN) and non–small-cell lung cancer (NSCLC) discuss recent data on the efficacy of targeted therapies—alone and in combination with other medications—in the treatment of both of these cancers. Common adverse effects that can occur with these agents are reviewed and management strategies are discussed. Molecular testing in SCCHN and NSCLC is highlighted. http://podcast.peerviewpress.com/oncology/PA02141FCinR162.mp3 http://podcast.peerviewpress.com/oncology/PA02141FCinR162.mp3 Tue, 10 Apr 2007 16:42:37 -0400 Science no 00:35:36 Head and neck cancer, HNSCC, SCCHN, NSCLC, non–small-cell lung cancer, EGFR inhibitors, monoclonal antibodies, metastatic disease, cetuximab, erlotinib, panitumumab, gefitinib, cisplatin, radiotherapy, paclitaxel, induction chemoradiation,